The history of Curasight

 The lead uPAR-PET tracer candidate from this research developed into Curasight’s uTRACE® product for cancer diagnosis. At the same time Curasight pursued the idea of using uPAR as a biomarker to create a theranostic platform solution – combining detection and classification of a tumor using uTRACE with subsequent improved treatment solutions for the cancer. This led to Curasight acquiring all the international patent rights (IP) to the radionuclide uTREAT®, Curasight’s product designed to treat certain types of tumors. Curasight is currently in Phase 2 with uTRACE and in preclinical testing with uTREAT.